



# RTP TV

NON-SMALL CELL  
LUNG CANCER

## Select Publications

Janjigian YY et al. **Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib.** *Proc ASCO 2011;Abstract 7525.*

Kreuter M et al. **Randomized phase II trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed (CPx) versus cisplatin and vinorelbine (CVb): TREAT.** *Proc ASCO 2011;Abstract 7002.*

Kris MG et al. **Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The Lung Cancer Mutation Consortium (LCMC).** *Proc ASCO 2011;Abstract CRA7506.*

Kwak EL et al. **Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.** *N Engl J Med 2010;363:1693-703. Abstract*

Langer CL et al. **The evolving role of histology in the management of advanced non-small-cell lung cancer.** *J Clin Oncol 2010;28(35):5311-20. Abstract*

Miller VA et al. **Phase IIb/III double-blind randomized trial of afatinib (BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2) + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung 1).** *Proc ESMO 2010;Abstract LBA1.*

Pao W, Girard N. **New driver mutations in non-small-cell lung cancer.** *Lancet Oncol 2011;12:175-80. Abstract*

Paz-Ares LG et al. **PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer.** *Proc ASCO 2011;Abstract CRA7510.*

Rosell R et al. **Erlotinib vs chemotherapy (CT) in advanced non-small-cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) activating mutations: Interim results of the European Erlotinib vs Chemotherapy (EURTAC) Phase III randomized trial.** *Proc ASCO 2011;Abstract 7503.*

Sequist LV et al. **Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.** *Sci Transl Med 2011;3(75):75ra26. Abstract*

Shaw AT et al. **Impact of crizotinib on overall survival of patients with advanced, ALK-positive NSCLC compared with historical controls.** *Proc ASCO 2011;Abstract 7507.*

Spigel DR et al. **Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMab or placebo in combination with erlotinib in advanced NSCLC.** *Proc ASCO 2011;Abstract 7505.*

Sznol M et al. **Safety and antitumor activity of biweekly MDX-1106 (anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies.** *Proc ASCO 2010*;Abstract 2506.

Zhang L et al. **Efficacy and tolerability data from a randomized, placebo-controlled, parallel-group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic NSCLC (INFORM) (C-TONG 0804).** *Proc ASCO 2011*;Abstract LBA7511.

**Chemotherapy with or without bevacizumab in treating patients with stage IB, stage II, or stage IIIA non-small lung cancer that was removed by surgery.** NCT00324805.